Patents Assigned to Vertex Pharmaceuticals (EUROPE) Limited
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20220041557
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: December 14, 2020
    Publication date: February 10, 2022
    Applicant: Vertex Pharmaceuticals (Europe) Limited
    Inventor: Adam J. Morgan
  • Deuterated CFTR potentiators
    Patent number: 10894773
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: January 19, 2021
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventor: Adam J. Morgan
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20200290971
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: October 22, 2019
    Publication date: September 17, 2020
    Applicant: Vertex Pharmaceuticals (EUROPE) Limited
    Inventor: Adam J. Morgan
  • Deuterated CFTR potentiators
    Patent number: 10759721
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: September 1, 2020
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: Adam J. Morgan, Roger D. Tung
  • Deuterated CFTR modulators
    Patent number: 10738036
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: I. Robert Silverman, Roger D. Tung
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20190169129
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: July 12, 2018
    Publication date: June 6, 2019
    Applicant: Vertex Pharmaceuticals (EUROPE) Limited
    Inventor: Adam J. Morgan
  • Deuterated CFTR modulators
    Patent number: 10196384
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: February 5, 2019
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: I. Robert Silverman, Roger D. Tung
  • Deuterated CFTR potentiators
    Patent number: 10047053
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: August 14, 2018
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventor: Adam J. Morgan
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20180086711
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 29, 2018
    Applicant: Vertex Pharmaceuticals (EUROPE) Limited
    Inventor: Adam J. Morgan